Health Dictionary Find a Doctor

Transitional cell carcinoma history and symptoms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Suveenkrishna Pothuru, M.B,B.S. [2]

Overview

The most common symptoms of transitional cell carcinoma of bladder include hematuria, urinary frequency, urinary urgency, and dysuria. The most common symptoms of transitional cell carcinoma of upper urinary tract include hematuria and pain in the flank or abdomen. Less common symptoms of transitional cell carcinoma include loss of appetite, weight loss, fatigue, and fever.

History

When evaluating a patient for transitional cell carcinoma, you should take a detailed history of the presenting symptom (duration, onset, progression), other associated symptoms, and a thorough past medical history review. Other specific areas of focus when obtaining the history are:[1]

  • Review of smoking history
  • Using pain medicines such as phenacetin for a long time
  • Any occupational or environmental risk factors such as being around dyes and chemicals used in making leather, textiles, rubber, or plastics

Common Symptoms

  • Clinical presentation is variable and usually non-specific.
  • Tumors may also result in obstruction and symptomatic hydronephrosis.
  • Occasionally there may be no symptoms in the early stages and present once systemic symptoms of metastatic disease are present.
  • Symptoms of transitional cell carcinoma may include:[1][2][3]

Transitional Cell Carcinoma of Bladder

Transitional Cell Carcinoma of Pelvis and Ureter

Less Common Symptoms

References

  1. 1.0 1.1 Risk factors for brain and spinal cord cancer. Canadian Cancer Society(2015) http://www.cancer.ca/en/cancer-information/cancer-type/renal-pelvis-and-ureter/diagnosis/?region=ab Accessed on February, 17 2016
  2. Transitional cell cancer. National cancer institute. http://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq
  3. Kirkali, Ziya; Tuzel, Emre (2003). “Transitional cell carcinoma of the ureter and renal pelvis”. Critical Reviews in Oncology/Hematology. 47 (2): 155–169. doi:10.1016/S1040-8428(03)00079-9. ISSN 1040-8428.

Template:WH Template:WS

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH